Single-agent high-dose melphalan (HDM, 200 mg/m 2 ) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to overcome early relapse and combat drug resistance. We present a retrospective comparison and long-term follow-up of newly diagnosed patients with multiple myeloma (MM) treated with induction followed by either high-dose carmustine (BCNU) and HDM, or HDM alone, both followed by autologous stem cell transplant (ASCT). Between 1997 and 2002, 104 patients were treated with BCNU/HDM; from 2001 to 2008, 103 patients were treated with HDM alone. Median follow-up of survivors was 78 and 68 months for the BCNU/HDM and HDM groups, respectively. The median PFS was significantly increased with the BCNU/HDM regimen (40.4 vs 20.5 months, P o 0.001). Median overall survival was increased with the BCNU/HDM regimen when compared with HDM alone (88.4 vs 67.2 months, P = 0.07), but the difference was not statistically significant. Transplant-related mortality was similar in both groups (2.9% with BCNU and HDM vs 3.9% with HDM alone). Our findings suggest that the BCNU/HDM preparative regimen should be investigated further and potentially compared in a prospective randomized manner with HDM alone.
INTRODUCTION
Induction therapy followed by high-dose chemotherapy and autologous stem cell rescue represents a well-established strategy to achieve high response rates and extended PFS in newly diagnosed multiple myeloma (MM) compared with chemotherapy alone. [1] [2] [3] [4] [5] Even in our current era of novel agents, studies have shown that high-dose chemotherapy followed by autologous stem cell transplant (ASCT) remains the ideal treatment option for patients with newly diagnosed MM with good performance status. These studies have shown that when compared directly with therapy with newer agents, transplant continues to confer a superior benefit on PFS. 6, 7 Furthermore, the use of early intensive ASCT-based therapy may further maximize clonal restriction early in the treatment timeline when compared with chemotherapy alone, leading to improved survival outcomes. 8 A number of studies have shown that patients achieving higher pre-and post-transplant response rates have longer PFS and overall survival (OS) compared with patients achieving suboptimal responses (PR). Improved response rates may be achieved via optimizing both the induction therapy and transplant conditioning regimen. Several studies using combinations of newer agents including bortezomib and immunomodulatory drugs in the induction setting before transplant have resulted in higher response rates that have directly translated into improved outcomes following ASCT. [9] [10] [11] [12] In contrast, efforts to optimize transplant conditioning regimens have not resulted in improved responses with acceptable toxicity to date. The most widely used conditioning regimen in preparation for ASCT for MM is a single dose of high-dose melphalan (HDM, 200 mg/m 2 ) followed by stem cell rescue, reported in 1992 by the Arkansas Group. 13 Other groups attempted to improve outcomes through dose intensification or the addition of TBI, but although the response rates were similar, OS and tolerability were significantly superior with the use of HDM alone.
14 Different regimens including high-dose busulfan, busulfan/cyclophosphamide, busulfan/HDM, thiotepa/busulfan/ cyclophosphamide and busulfan/cyclophosphamide/etoposide have been retrospectively compared with HDM. In the majority of these studies, PFS and OS after transplant were similar. These studies showed an improvement of PFS, but at the expense of increased toxicity and transplant-related mortality. [15] [16] [17] [18] [19] [20] Carmustine (BCNU) is an alkylating chemotherapy agent that has been successfully used in combination with other alkylating agents for the treatment of lymphoma and was therefore tested in myeloma as well. In these studies, BCNU was found to have activity in both the upfront and salvage settings. [21] [22] [23] In addition, induction therapy followed by high-dose cyclophosphamide and then high-dose VP16 followed by BCNU (15 mg/kg) plus HDM and ASCT was shown to improve PFS compared with historical controls of single-agent HDM followed by ASCT. These improved outcomes were observed alongside a relatively manageable toxicity profile. 24 Based on these experiences, we combined BCNU and HDM (BCNU/HDM) as a conditioning regimen before ASCT and retrospectively examined its effect on MM disease response, PFS, OS and toxicity in newly diagnosed patients. These outcomes were 1 then compared with a subsequent group of patients treated with HDM alone.
MATERIALS AND METHODS Patients
We reviewed all individuals with MM seen at our institution from 1997 to December 2008 who underwent induction followed by high-dose therapy and ASCT and analyzed the results through October 2016. Subjects were excluded from this analysis if they were transplanted beyond 2 years of diagnosis, received ASCT as part of a tandem transplant, primed with G-CSF alone, received an ASCT followed by an allogeneic stem cell transplant or received maintenance therapy after ASCT. Between Toxicity and response assessments Subjects were followed daily for toxicity following CTCAE (Common Terminology Criteria for Adverse Events) criterion (versions 1.0, 2.0 or 3.0, depending on year of treatment) until engraftment and had a planned evaluation of pulmonary function at 6 weeks following transplant, and then were followed as clinically indicated. PFS was established from day 0 post transplant to the time of disease progression/relapse or death, whereas OS was established from the completion of transplant to the date of death from any cause. A CR was defined as negative immunofixation of serum and urine, disappearance of soft tissue plasmacytoma and o 5% plasma cells in the bone marrow. Very good PR was defined as 490% reduction of serum M-protein or reduction of urine M-spike o 200 mg/ 24 h. Stable disease was defined as failure to meet any response criteria.
Responses were recorded before auto-SCT, and at day 100 post transplant using the International Myeloma Working Group criteria. Three patients with non-secretory MM could not be assessed for response.
Statistical analysis
Patient characteristics among the treatment groups were compared using Pearson's χ 2 test (or Fisher's exact test when cell counts were o5) and the Mann-Whitney U-test with a significance level of 0.05 for categorical and continuous data, respectively. Treatment responses were compared using the Pearson's χ 2 test, whereas the Kaplan-Meier plots with a log-rank test was used to compare the PFS and OS among the treatment groups. The Wald test in a proportional hazards model was used to test for the effect of age on PFS and OS within the treatment groups. All analyses were performed using statistical software R (Durham, NC, USA).
RESULTS

Patients
In all, 422 patients with newly diagnosed, previously untreated MM were evaluated at our institution between 1997 and 2008. Of these, 215 patients were excluded because of receiving an ASCT beyond 2 years of diagnosis (28%), having a tandem ASCT (26%), having nonchemotherapy mobilization (37%) or having ASCT followed by an allogeneic transplant (9%). Thus, 207 patients were included in this retrospective analysis. As shown in Table 1 , there were no significant differences in disease stage before transplant using either the Durie-Salmon staging system or the International Staging System. The median age on the BCNU/HDM group was 54 years compared with 58 years in the HDM group (P = 0.003). We used a proportional hazards model to test for the effect of age on post transplant survival and found that age was not statistically significant using this multivariate analysis (P = 0.30). Patients High-dose BCNU/Melphalan conditioning regimen before ASCT in MM D Sivaraj et al treated with BCNU/HDM were diagnosed preceding the introduction of newer anti-myeloma agents including thalidomide, lenalidomide and bortezomib and therefore were not able to receive these agents as induction therapy. The cohort of patients treated with HDM received various combinations of these novel agents as induction therapy because of the more recent time period in which they were treated (Table 2 ). In all, 24 patients in the BCNU/HDM group and 28 patients in the HDM group received more than one induction therapy in preparation for transplant. Interestingly, disease status pretransplant was not significantly different between the two groups as 22 patients in the BCNU/HDM cohort and 28 in the HDM were in very good PR or better before transplant (P = 0.10).
Transplant-related toxicity All transplants were conducted in the outpatient setting, although 25 (24%) and 34 (33%) patients in the BCNU/HDM and HDM groups, respectively, were admitted to the hospital for transplantrelated complications. Gastrointestinal toxicity was similar between the two groups, but pulmonary-related side effects, namely pneumonitis (confirmed by a decrease in the lung diffusion capacity (DLCOc) by at least 25%), were significantly higher with the BCNU/HDM group (48% vs 15% with HDM). This toxicity was manageable with early recognition and a short course of steroids and was never fatal. Three patients given BCNU/HDM died within 6 months of ASCT because of disseminated fungal infection (1), renal failure (1) and sepsis (1). In the HDM group, 4 patients died within 6 months, all because of infection (Table 3) .
Post transplant outcomes Interestingly, post-transplant responses were similar between the two treatment groups (P = 0.84; Table 4 ). The median follow-up for surviving patients in the BCNU/HDM and HDM cohorts were 78 and 68 months, respectively. The post-transplant PFS was significantly increased in the BCNU/HDM group as compared with the HDM group (P o0.001), with median survival times of 40.4 months (95% confidence interval (CI), 32.7-52.6) and 20.5 months (95% CI, 16.7-25.4) respectively (Figure 1) . The percentage of patients surviving at least 10 years without progression from time of transplant was 21% in the BCNU/HDM group and 7% in the HDM group. The OS was increased in the BCNU/HDM group with a median OS of 88.4 months (95% CI, 63.8-126) with BCNU/HDM vs 67.2 (95% CI, 49.8-108) months with HDM, but this difference was not statistically significant ( Figure 2) . The percentage of patients surviving at least 10 years from time of transplant was 43% in the BCNU/HDM group and 26% in the HDM group. Abbreviation: HDM = high-dose melphalan. Abbreviations: HDM = high-dose melphalan; MR = minimal response; PR = partial response; VGPR = very good PR. High-dose BCNU/Melphalan conditioning regimen before ASCT in MM D Sivaraj et al DISCUSSION Even in our era of novel agents, high-dose chemotherapy followed by ASCT remains standard of care and represents an important treatment strategy to significantly reduce tumor burden and maximize clonal restriction early in the disease course. 6, 8 Although studies have shown a benefit to both PFS and OS, most patients will eventually relapse after transplantation. In this report, we summarize a single institution experience comparing two conditioning regimens (BCNU/HDM vs single agent HDM) in MM as preparation for ASCT. Our study demonstrates and confirms earlier reports of the relative safety of BCNU/HDM as a high-dose chemotherapy regimen. In both groups examined, time to engraftment was similar, toxicities were manageable, and treatment-related mortality was identical. As noted by others, rates of interstitial pneumonitis were significantly increased in the BCNU/HDM group (48% vs 15%). Patients developing pneumonitis were successfully treated with a short course of steroids in an outpatient setting. Prophylaxis with steroid inhaler for 60 days post transplant in an attempt to decrease the incidence of pneumonitis may further reduce the toxicity of this regimen. 25 In addition, our findings extend to those reported by Chen et al., 24 although our study did not include tandem chemo-mobilization with etoposide, has a longer follow-up, uses a different dosage of BCNU and includes additional comparison with a subsequent group treated with HDM alone at the same institution. Based on these results, we are able to demonstrate that BCNU/HDM has meaningful activity against MM. An abstract by Neppalli et al. 26 at ASCO (American Society of Clinical Oncology) 2016 presented long-term outcomes of BCNU/HDM conditioning followed by ASCT for patients with MM. This study analyzed 414 patients who received BCNU (350 mg/m 2 ) and melphalan (200 mg/m 2 ) between 2006 and 2015. Incidence of pneumonitis was significantly lower in this study (25%) compared with ours (48%), and can most likely be attributed to the lower dosage of BCNU used. 26 This suggests the potential for future dose optimization from the BCNU dosage used in our study (500 mg/m 2 ) down to one that improves toxicity while retaining the significant efficacy observed with this regimen. Our study showed that conditioning with BCNU/HDM before ASCT demonstrated an improved PFS compared with patients treated with HDM. The group treated with HDM failed to achieve a plateau in the PFS curve observed in the BCNU/HDM group, similar to results from prior studies investigating outcomes of patients receiving HDM without maintenance therapy post transplant (Figure 2) . 27, 28 Of note, the 10-year overall survival rate of 43% following BCNU/HDM and ASCT without consolidation and/or maintenance therapy is higher than that of the national average based on the National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) program. 29 The high percentage of patients in the BCNU/HDM group surviving over 10 years is significant, given that these individuals were treated with suboptimal induction therapies and did not receive consolidation or maintenance therapy post transplantation. Importantly, at the time of relapse, many patients in the BCNU/HDM group did not have access to the same quantity of available therapies as those treated in the HDM group. This is a result of the two different time periods at which these groups were treated. It is possible that the lack of a statistically significant difference that we see in OS between the two groups could be at least partially attributed to this circumstance.
Patient inclusion into this retrospective study for the HDM group was cut off at year 2008 so as to not include patients who received maintenance therapy post ASCT that has been shown to significantly extend PFS and potentially affect OS post transplant. 27, 30 Thus, neither the BCNU/HDM nor HDM group in our study received maintenance therapy after ASCT. Although our findings are limited by the retrospective nature of this study, it is important to note that patients in the BCNU/HDM group were treated in a different time period than the HDM group, and therefore did not benefit from improvements in supportive care, novel induction therapies and many of the novel therapies that were available to the HDM group at the time of relapse. Another limitation relates to the absence of cytogenetic data available that would have been important to elucidate the relative levels of disease disposition in both groups, as well as to stratify PFS and OS based on high-risk and standard-risk features. The availability of cytogenetic data would have helped confirm the prognostic comparability of the two groups; however, during the time period during which the individuals in this study were treated, cytogenetic analysis was not routinely performed. The sizeable length of time during which our analysis was conducted meant that patients were characterized using different versions of the CTC criteria depending on the year during which they received treatment. However, we do not believe that this variation affected our toxicity results to an appreciable extent. The significant posttransplant follow-up in the BCNU/HDM and HDM groups (78 and 68 months, respectively) strengthens the durability of our findings. In addition, the similarities in PFS between our HDM group and recent historical controls of patients treated with HDM alone with no maintenance therapy supports the external validity of our data. 27 The improvement in PFS with BCNU/HDM is promising, but the reasons underlying the observed efficacy are unclear. We can speculate that BCNU may more effectively target potential 'myeloma stem cells' that elude HDM alone. Another possibility is that BCNU could have effects on the bone marrow microenvironment, thus rendering MM cells more susceptible to chemotherapy. 31, 32 Our finding that 21% of patients treated with BCNU/HDM remained without evidence of progressive disease over 10 years post transplant in the absence of any additional maintenance therapy suggests that a distinct effect is occurring with this combination, as this number is measurably higher than that experienced with HDM alone. 1, 27, 28 The growing evidence of clonal heterogeneity and evolution throughout the myeloma disease course has been supported by genomic studies showing that patient myeloma cell populations experience both linearly derived and branching clonal evolution. 33, 34 We can consider the imposition of sequential therapies as selective environmental pressures that eventually favor the expansion of more aggressive and drug resistant disease subclones. 30 This viewpoint supports the development of welltolerable preparative regimens combining synergistic agents to achieve deeper responses and maximize clonal restriction early on in the treatment timeline. Even in our era of novel agents, the fact remains that myeloma remains an incurable disease. Each treatment acts as a selective pressure for the dominance of more aggressive subclones, leading to shorter periods of remission after every subsequent line of therapy. Therefore, optimizing the transplant conditioning regimen should receive significant attention for innovation in order to maximize clonal restriction early on and mitigate the potential for rapid disease evolution. 35 Our findings suggest that the combination of BCNU/HDM would benefit from being studied in a prospective randomized manner in the relapsed and/or newly diagnosed setting. Ultimately, a phase III study comparing induction with novel therapies followed by randomization to either BCNU/HDM or HDM alone before ASCT for patients with newly diagnosed MM would provide valuable insight into the utility of this combination. Dose optimization to reduce the incidence of pneumonitis is warranted, as well as correlative laboratory studies to provide insights into possible mechanistic explanations for improvements in outcomes with BCNU/HDM, if they were to be confirmed in a controlled study.
In summary, both PFS and OS were superior with the BCNU/HDM regimen compared with HDM alone, and a sizeable subgroup of patients treated with BCNU/HDM achieved long-term PFS and OS. Engraftment and treatment-related mortality were similar in both groups despite advances in supportive care for the HDM group. Unfortunately, the lack of cytogenetic data available in both groups limits the prognostic comparability to a degree. Our findings suggest that BCNU/HDM proved to be an efficacious treatment modality and should be compared in a prospective manner to HDM as an ASCT preparative regimen to determine whether this strategy could achieve a greater increase in cytoreduction, time to progression, and OS.
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